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Andrographolide (AGP), a naturally occurring bioactive compound, has been investigated as 
a lead compound in cancer drug development. Its multidimensional therapeutic effects have 
raised interest among medicinal chemists, which has led to extensive structural modification 
of the compound, resulting in analogues with improved pharmacological and pharmaceutical 
properties. Nevertheless, the analogues with the improved properties need to be rigorously 
studied to identify drug-like lead compounds. We scrutinised articles published from 2012 to 
2018, to objectively provide opinions on the mechanisms of action of AGP and its analogues, 
as well as their potential as viable anticancer drugs. Preclinical and clinical data, along with 
the extensive medicinal chemistry efforts, indicate the compounds are potential anticancer 
agents with specific value in treating recalcitrant cancers such as pancreatic and lung cancers. 
